The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1360
NitroMist Nitroglycerin Spray for Angina
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a lingual aerosol formulation of nitroglycerin (NitroMist – Akrimax) for acute relief of an attack or acute prophylaxis of angina pectoris. It is the second nitroglycerin lingual spray to become available in the US; Nitrolingual Pumpspray was approved in 1985. Most patients with angina use sublingual nitroglycerin tablets.

PHARMACOKINETICS — After being sprayed on or under the tongue, nitroglycerin can be detected in plasma within 2 minutes, and levels persist for up to 90 minutes. It is metabolized mainly in the liver, partly to active metabolites that have a half-life of 40 minutes.

CLINICAL STUDIES — In an unpublished trial in 30 patients with stable angina, summarized in the package insert, single doses of 0.2, 0.4 and 0.8 mg of NitroMist significantly prolonged exercise duration to development of moderate angina by 1.2, 1.6 and 1.7 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: NitroMist Nitroglycerin Spray for Angina
Article code: 1360b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian